Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 3/2012

01-06-2012 | Neuropathic Pain (R Raja, Section editor)

HIV-Associated Sensory Neuropathy: Risk Factors and Genetics

Authors: Peter R. Kamerman, Antonia L. Wadley, Catherine L. Cherry

Published in: Current Pain and Headache Reports | Issue 3/2012

Login to get access

Abstract

HIV-associated sensory neuropathy (HIV-SN) remains a common neurological complication of HIV infection despite the introduction of effective antiretroviral therapies. Exposure to neurotoxic antiretroviral drugs and increasing age have consistently been identified as risk factors for HIV-SN, while comorbid conditions with underlying predisposition to cause peripheral neuropathy (eg, diabetes mellitus, malnutrition, isoniazid exposure), ethnicity, and increasing height also have been implicated. Genetic association studies have identified genes affecting mitochondrial function and genes involved in the inflammatory response that modify the risk for HIV-SN among patients exposed to neurotoxic antiretrovirals. However, there is a lack of data on clinical, demographic, and genetic risk factors for HIV-SN in the modern era, with the rate of HIV-SN remaining unacceptably high despite the introduction of safer medications. Thus, more work is required to identify the principal factors that increase an individual’s risk for HIV-SN so that effective preventative or therapeutic strategies can be implemented.
Literature
1.
Brew BJ. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve. 2003;28:542–52.PubMedCrossRef
2.
Cherry C, McArthur J, Hoy J, et al. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol. 2003;26:195–207.PubMedCrossRef
3.
4.
5.
Johnson D, Corthals S, Walker B, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011;29:797–804.PubMedCrossRef
6.
Nikitin A, Chudakova D, Strokov I, et al. Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose)polymerase-1 gene are associated with diabetic polyneuropathy in Russian type 1 diabetic patients. Diabetes Res Clin Pract. 2008;79:446–52.PubMedCrossRef
7.
Tapp R, Shaw J, de Courten M, et al. Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med. 2003;20:105–13.PubMedCrossRef
8.
•• Cherry C, Affandi J, Imran D, et al. Age and height predict neuropathy risk in HIV patients prescribed stavudine. Neurology. 2009;73:315–20. This is a multicenter study showing that age and height are consistent risk factors for HIV-SN across diverse population groups.PubMedCrossRef
9.
• Maritz J, Benatar M, Dave J, et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve. 2010;41:599–606. This article describes risk factors for HIV-SN in black African HIV-positive patients exposed to antiretroviral therapy and patients who were treatment naïve.PubMed
10.
Shurie J, Deribew A. Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals. Ethiop Med J. 2010;48:85–93.PubMed
11.
Smyth K, Affandi J, McArthur J, et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993–2006. HIV Med. 2007;8:367–73.PubMedCrossRef
12.
Wright E, Brew B, Arayawichanont A, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology. 2008;71:50–6.PubMedCrossRef
13.
• Wadley A, Cherry C, Price P, et al. HIV neuropathy risk factors and symptom characterization in Stavudine-Exposed South Africans. J Pain Symptom Manage. 2011;41:700–6. This article provides a description of the symptomatology and risk factors for HIV-SN in black Africans.PubMedCrossRef
14.
Tagliati M, Grinnell J, Godbold J, et al. Peripheral nerve function in HIV infection. Clinical, electrophysiologic, and laboratory findings. Arch Neurology. 1999;56:84–9.CrossRef
15.
Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008;9:660–74.PubMedCrossRef
16.
Kamerman P, Mitchell D. Current perspectives on HIV-related pain and its management: insights from sub-Saharan Africa. Pain Manage. 2011;1:587–96.CrossRef
17.
Beadles W, Jahn A, Weigel R, et al. Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi. Trop Doct. 2009;39:78–80.PubMedCrossRef
18.
•• Phillips T, Cherry C, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5:e14433. This is an excellent review and meta-analysis of randomized controlled clinical trials investigating the pharmacological treatment of painful HIV-SN.PubMedCrossRef
19.
Bouhassira D, Attal N, Willer J-C, et al. Painful and painless peripheral sensory neuropathies due to HIV infection: a comparison using quantitative sensory evaluation. Pain. 1999;80:265–73.PubMedCrossRef
20.
Huengsberg M, Winer J, Ross J, et al. Thermosensory threshold: a sensitive test of HIV associated peripheral neuropathy? J Neurovirol. 1998;4:433–7.PubMedCrossRef
21.
•• Ellis R, Rosario D, Clifford D, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010;67:552–8. This is the first study to report on the continued high prevalence of HIV-SN in patients receiving modern cART.PubMedCrossRef
22.
Kandiah P, Atadzhanov M, Kvalsund M, et al. Evaluating the diagnostic capacity of a single-question neuropathy screen (SQNS) in HIV positive Zambian adults. J Neurol Neurosurg Psychiatry. 2010;81:1380–1.PubMedCrossRef
23.
Robinson-Papp J, Morgello S, Vaida F, et al. Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. Pain. 2010;151:732–6.PubMedCrossRef
24.
Cherry C, Wesselingh S, Lal L, et al. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology. 2005;65:1778–81.PubMedCrossRef
25.
Barohn R, Gronseth G, LeForce B, et al. Peripheral nervous system involvement in a large cohort of Human Immunodeficiency Virus-infected individuals. Arch Neurol. 1993;50:167–70.PubMedCrossRef
26.
So Y, Holtzman D, Abrams D, et al. Peripheral neuropathy associated with Acquired Immunodeficiency Syndrome—Prevalence and clinical features from a population-based survey. Arch Neurol. 1988;45:945–8.PubMedCrossRef
27.
Childs E, Lyles R, Selnes O, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607–13.PubMed
28.
Woolley I, Faragher M, Ugoni A, et al. An analysis of factors associated with HIV-related peripheral neuropathy. Neurol Infect Epidemiol. 1997;1997:33–7.
29.
Forna F, Liechty C, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007;44:456–62.PubMedCrossRef
30.
• Kamerman P, Moss P, Weber J, et al.: Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J Peripher Nerv Syst 2012, In press. This is a concise review of the pathogenesis of HIV-SN based on in vivo and in vitro models of the neuropathy.
31.
•• Choi Y, Townend J, Vincent T, et al. Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. J Neurovirol. 2011;17:166–75. This article provides invaluable data on the neurological complications of HIV-2 infection.CrossRef
32.
Dalakas M, Yarchoan R, Spitzer R, et al. Treatment of human immunodeficiency virus-related polyneuropathy with 3′-azido-2′,3′–dideoxythymidine. Ann Neurology. 1988;23:S92–4.CrossRef
33.
Markus R, Brew B. HIV-1 peripheral neuropathy and combination antiretroviral therapy. Lancet. 1998;352:1906–7.PubMedCrossRef
34.
Bacellar H, Munoz A, Miller E, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology. 1994;44:1892–900.PubMed
35.
Ances B, Vaida F, Rosario D, et al. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS. 2009;23:2317–22.PubMedCrossRef
36.
Kumarasamy N, Venkatesh K, Cecelia A, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS. 2008;22:227–44.
37.
Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007;45:305–10.
38.
Nakamoto BK, McMurtray A, Davis J, et al. Incident neuropathy in HIV-infected patients on HAART. AIDS Res Hum Retroviruses. 2010;26:759–65.PubMedCrossRef
39.
• Anziska Y, Helzner EP, Crystal H, et al. The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. J Neurol Sci 2011, doi: 10.​1016/​j.​jns.​2011.​11.​009. This was the first study to report an association between HIV-SN and being of African descent.
40.
Browne M, Mayer K, Chafee S, et al. 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993;167:21–9.PubMedCrossRef
41.
Lambert J, Seidlin M, Reichmann R, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial N Engl J Med. 1990;322:1333–40.
42.
Yarchoan R, Perno C, Thomas R, et al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988;1:76–81.PubMedCrossRef
43.
44.
Esteban P, Thahn T, Bravo J, et al. Malnutrition associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection. J Acquir Immune Defic Syndr. 2009;52:656–568.PubMed
45.
Ferrari L, Levine J. Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms. Eur J Neurosci. 2010;32:811–8.PubMedCrossRef
46.
Cheng Y, Gregg E, Kahn H, et al. Peripheral insensate neuropathy-a tall problem for US adults? Am J Epidemiol. 2006;164:873–80.PubMedCrossRef
47.
Shikuma C, Ananworanich J, Valcour V, et al. Correlates of epidermal nerve fiber density in HIV-infected individuals without neuropathy prior to initiation of potent ART [abstract 173]. Presented at 17th Conf Retrovir Oppor Infect. San Francisco, USA; February 16–19, 2010.
48.
Menezes C, Maskew M, Sanne I, et al. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011;11:244.PubMedCrossRef
49.
Sacktor N, Nakasujja N, Skolasky R, et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology. 2009;72:165–70.PubMedCrossRef
50.
•• Mehta S, Ahmed A, Laverty M, et al. Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis. 2011;53:490–6. This is an excellent prospective, longitudinal study on the incidence of HIV-SN in patients starting stavudine-based treatment.PubMedCrossRef
51.
Lichtenstein K, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. CLin Infect Dis. 2005;40:148–57.PubMedCrossRef
52.
Pettersen J, Jones G, Worthington C, et al. Sensory Neuropathy in Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006;59:816–24.PubMedCrossRef
53.
Evans S, Ellis R, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS. 2011;25:919–28.PubMedCrossRef
54.
Ellis R, Marquie-Beck J, Delaney P, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008;64:566–72.PubMedCrossRef
55.
Cherry C, Affandi J, Brew B, et al. Ethnicity is an independent predictor of neuropathy risk in HIV patients [abstract 416]. Presented at 18th Conf Retrovir Oppor Infect. Boston, USA; 27 February - 2 March, 2011.
56.
Cherry C, Affandi J, Brew B, et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among HIV patients. Neurology. 2010;74:1538–42.PubMedCrossRef
57.
Clifford D, Smurzynski M, Park L, et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology. 2009;73:309–14.PubMedCrossRef
58.
Sithinamsuwan P, Punthanamongkol S, Valcour V, et al. Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand. J Acquir Immune Defic Syndr. 2008;49:456–8.PubMedCrossRef
59.
Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV1-seropositive pregnant women in mazambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007;44:371–6.PubMedCrossRef
60.
Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. The Manhattan HIV Brain Bank. Arch Neurol. 2004;61:546–51.PubMedCrossRef
61.
Schifitto G, McDermott M, McArthur J, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology. 2005;64:842–8.PubMedCrossRef
62.
Attal N, Lanteri-Minet M, Laurent B, et al. The specific disease burden of neuropathic pain: Results of a French nationwide survey. Pain. 2011;152:2836–43.PubMedCrossRef
63.
Simpson DM, Haidich AB, Schifitto G, et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS. 2002;16:407–12.PubMedCrossRef
64.
Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology. 2002;58:115–9.PubMed
65.
Zhou L, Kitch DW, Evans SR, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology. 2007;68:2113–9.PubMedCrossRef
66.
Lucey B, Clifford D, Creighton J, et al. Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care. 2011;23:921–8.PubMedCrossRef
67.
Evans S, Weinberg BA, Spielman L, et al. Assessing negative thoughts in response to pain among people with HIV. Pain. 2003;105:239–45.PubMedCrossRef
68.
69.
Hahn K, Triolo A, Hauer P, et al. Impaired reinnervation in HIV infection following experimental denervation. Neurology. 2007;68:1251–6.PubMedCrossRef
70.
Mills E, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209–16.PubMed
71.
van Sighem A, Gras L, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527–35.PubMedCrossRef
72.
Winkler C. Is there a genetic basis for health disparities in human immunodeficiency virus disease? Mt Sinai J Med. 2010;77:149–59.PubMedCrossRef
73.
Macgregor S, Cornes BK, Martin NG, et al. Bias, precision and heritability of self-reported and clinically measured height in Australian twins. Hum Genet. 2006;120:571–80.PubMedCrossRef
74.
Perola M, Sammalisto S, Hiekkalinna T, et al. Combined genome scans for body stature in 6,602 European twins: evidence for common Caucasian loci. PLoS Genet. 2007;3:e97.PubMedCrossRef
75.
Silventoinen K, Sammalisto S, Perola M, et al. Heritability of adult body height: a comparative study of twin cohorts in eight countries. Twin Res. 2003;6:399–408.PubMed
76.
Costarelli S, Torti C, Gatta LB, et al. No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. J Acquir Immune Defic Syndr. 2007;46:255–6.PubMedCrossRef
77.
Canter JA, Haas DW, Kallianpur AR, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J. 2008;8:71–7.PubMedCrossRef
78.
• Canter JA, Robbins GK, Selph D, et al. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis. 2010;201:1703–7. This is the first study to investigate population-specific mitochondrial risk factors for HIV-SN in individuals of African descent.PubMedCrossRef
79.
Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005;19:1341–9.PubMedCrossRef
80.
Chen X, Goudsmit J, van der Kuyl AC. Lack of correlation between length variation in the DNA polymerase gamma gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment. AIDS Res Hum Retroviruses. 2002;18:531–4.PubMedCrossRef
81.
Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS. 2006;20:1503–13.PubMedCrossRef
82.
Affandi JS, Price P, Imran D, et al. Can we predict neuropathy risk before stavudine prescription in a resource-limited setting? AIDS Res Hum Retroviruses. 2008;24:1281–4.PubMedCrossRef
83.
Cherry CL, Rosenow A, Affandi JS, et al. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual’s NRTI-SN risk. AIDS Res Hum Retroviruses. 2008;24:117–23.PubMedCrossRef
84.
• Chew CSN, Cherry CL, Imran D, et al. Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients. Tissue Antigens. 2011;77:126–30. This article demonstrates the importance of genes in the central MHC as risk factors for HIV-SN across ethnic groups.PubMedCrossRef
85.
Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol. 2010;6:1493–504.PubMedCrossRef
86.
Chan SS, Copeland WC. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. Biochim Biophys Acta. 2009;1787:312–9.PubMedCrossRef
87.
Parkkila S, Niemela O, Britton RS, et al. Molecular aspects of iron absorption and HFE expression. Gastroenterology. 2001;121:1489–96.PubMedCrossRef
88.
Horowitz MP, Greenamyre JT. Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis. 2010;20 Suppl 2:S551–68.PubMed
89.
90.
Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol. 2001;154:193–206.PubMedCrossRef
91.
92.
•• Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics. 2009;10:623–37. This is an excellent review of the genetic risk factors associated with risk of NRTI-induced HIV-SN.PubMedCrossRef
93.
94.
Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med. 2006;12:1269–77.PubMedCrossRef
95.
Wadley AL, Lombard Z, Cherry CL, Price P, Kamerman PR. Analysis of a previously identified 'pain protective' haplotype and individual polymorphisms in the GCH1 gene in Africans with HIV-associated sensory neuropathy: a genetic association study. J Acquir Immune Defic Syndr 2012, In press.
96.
Dorsey SG, Leitch CC, Renn CL, et al. Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathy. Biol Res Nurs. 2009;11:7–16.PubMedCrossRef
97.
Maratou K, Wallace VCJ, Hasnie FS, et al. Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur J Pain. 2009;13:387–98.PubMedCrossRef
Metadata
Title
HIV-Associated Sensory Neuropathy: Risk Factors and Genetics
Authors
Peter R. Kamerman
Antonia L. Wadley
Catherine L. Cherry
Publication date
01-06-2012
Publisher
Current Science Inc.
Published in
Current Pain and Headache Reports / Issue 3/2012
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-012-0257-z

Other articles of this Issue 3/2012

Current Pain and Headache Reports 3/2012 Go to the issue

Migraine Headache (F Taylor, Section Editor)

Migrainous Infarction: Aspects on Risk Factors and Therapy

Neuropathic Pain (R Raja, Section editor)

Spinal Cord Injury Pain: Mechanisms and Management

Migraine Headache (F Taylor, Section Editor)

Endogenous Mechanisms Underlying the Activation and Sensitization of Meningeal Nociceptors: The Role of Immuno-Vascular Interactions and Cortical Spreading Depression

Migraine Headache (F Taylor, Section Editor)

Why HURT? A Review of Clinical Instruments for Headache Management

Neuropathic Pain (R Raja, Section editor)

Spinal Cord Stimulation: Neurophysiological and Neurochemical Mechanisms of Action

Neuropathic Pain (R Raja, Section editor)

Epidemiology of Neuropathic Pain and Its Impact on Quality of Life